focus -WSS

focus

author：leisure time 2025-08-12 06:42:58 - browse：683

The Food and Drug Administration on Friday approved the world’s first medicine based on CRISPR gene-editing technology, a groundbreaking treatment for sickle cell disease that delivers a potential cure for people born with the chronic and life-shortening blood disorder.

The new medicine, called Casgevy, is made by Vertex Pharmaceuticals and CRISPR Therapeutics. Its authorization is a scientific triumph for the technology that can efficiently and precisely repair DNA mutations — ushering in a new era of genetic medicines for inherited diseases.

In a clinical trial, Casgevy was shown to eliminate recurrent episodes of debilitating pain caused by sickle cell, which afflicts approximately 100,000 people in the U.S., a vast majority of whom are Black. The therapy, whose scientific name is exa-cel, is described as a potential cure because the genetic fix enabled by CRISPR is designed to last a lifetime, although confirmation will require years of follow-up.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Families look for replacement for GSK asthma drug Flovent

focus

WSS

Readout LOUD: Venture capital, Gilead, and more M&A

First over

State of the Union pitch: Bigger Medicare drug price negotiations

Devoted Health’s losses in Medicare Advantage persist

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

First over

entertainment

focus

knowledge

Medical records are filled with copy

$1 billion proposal to grow Boston, Massachusetts biotech

Dobbs anniversary: the lost opportunity of abortion as health care

Biden's 'march

Medical leaders decry Supreme Court decision on affirmative action

Families look for replacement for GSK asthma drug Flovent

Tori Bowie and the unacceptable rates of Black maternal death

Medicare drug price negotiation continues, as pharma counteroffers

Hepatitis C has a cure — but many Americans still lack access to it

Florida health officials providing scant details on measles cases

hotspot

Why Novartis is going to walk from its acquisition of MorphoSys

Lack of health data on LGBTQ+ people has serious consequences

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

Global cancer cases to surge 77% by 2050, WHO report says

hotspot

focus

focus

Wikipedia